Clinical Trials Directory

Trials / Completed

CompletedNCT03452085

The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II

Artificial Saliva in Diabetes Type II: a Randomized Registry Cross Over Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Certmedica International GmbH · Industry
Sex
All
Age
30 Years – 75 Years
Healthy volunteers
Not accepted

Summary

In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with each product. Whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin. The artificial saliva spray reduced the xerostomia and the inflammation or the oral tissue.

Detailed description

In diabetes Type II the xerostomia is a quite frequent symptom. The trial was conducted at a single center. Designed and implementing UNI EN ISO 14155:2012, STROBE statement Version 4 and was in conformity with the guidelines of the Declaration of Helsinki. The type of study was a randomized, cross over clinical trial to compare two treatments (artificial saliva spray (aldiamed(R) mouth spray) AS vs. (Tonimer(R) Throat Spray) TT . Twenty one subjects that were part of the epidemiological screening for asymptomatic vascular diseases conducted in the Irwin Lab3 of Spoltore (PE / Italy) The degree of xerostomia for the admission had to be at least \> 2 according to a semi-quantal scale (ranging from 0 to 6) and patients already under treatment for xerostomia or with xerostomia score \< 2, suffering from obesity, cancer, drug addiction or alcoholism were excluded. The patients had to follow a three day treatment with each product. Whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin. The study consisted of a preliminary selection during screening, the measurement of xerostomia and random allocation, first treatment period, wash out period and finally the second treatment period.

Conditions

Interventions

TypeNameDescription
DEVICEartificial saliva spray (AS)cross over design
OTHERmaritime throat spray (TT)cross over design

Timeline

Start date
2017-09-23
Primary completion
2017-11-04
Completion
2018-01-16
First posted
2018-03-02
Last updated
2018-03-02

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03452085. Inclusion in this directory is not an endorsement.